Brought to you by 
Lilly, Somatogen enter hemoglobin substitute collaboration
29 Apr 2015
Executive Summary
Lilly has licensed the rights in most of the world to Somatogen's hemoglobin substitute, rHb1.1, in exchange for up to $35mm in equity purchases and the assumption of worldwide development and manufacturing costs.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly, Somatogen enter hemoglobin substitute collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice